Advanced Enzyme Technologies Ltd.
Snapshot View

264.75 +0.75 ▲0.3%

16 August 2022, 04:01:00 PM
Volume: 19,210

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.advancedenzymes.com
Market Cap 2,962.05 Cr.
Enterprise Value(EV) 2,696.57 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 8.90 Trailing Twelve Months Ending 2022-06
Price-Earning Ratio (PE) 29.76 Trailing Twelve Months Ending 2022-06
Industry PE 32.02 Trailing Twelve Months Ending 2022-06
Book Value / Share 98.88 Trailing Twelve Months Ending 2022-06
Price to Book Value 2.68 Calculated using Price: 264.75
Dividend Yield 0.38 Period Ending 2022-03
No. of Shares Subscribed 11.18 Cr. 111,817,825 Shares
FaceValue 2
Company Profile
The company is a fully integrated enzyme manufacturing company driven by extensive focus on research and development (R&D) of various enzymes, enzyme blends, enzyme products and customized enzyme solutions. Its experienced and qualified R&D team strives to develop creative, cost-effective unique and innovative solutions, thereby enabling their customers to develop superior products and processes. The company products assist its customers in making most of their resources, optimizing their processes, improving their product quality, saving their time and money while also mitigating the impact on the environment. It supplies these value-added and eco-safe enzyme products to diverse end-user industries like human healthcare and nutrition, animal nutrition, food processing, baking, dairy and cheese processing, fruit and vegetable processing, cereal extraction, brewing, grain processing, protein processing, oil and fat processing, biomass processing, textile processing, leather processing, paper & pulp processing, bio-fuels, bio-catalysis etc. Although, the company has the capability to manufacture enzymes using all the four natural origins viz. plant, animal, bacterial and fungal, their major focus is on developing enzymes through microbial fermentation.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.28%
1 Week
-5.06%
1 Month
-3.08%
3 Month
-3.11%
6 Month
-13.90%
1 Year
-31.02%
2 Year
+22.15%
5 Year
-10.19%
10 Year
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 12.70 27.31 31.32 25.06 18.34 18.82 17.61 16.77 12.04
Return on Capital Employed (%) 12.25 25.49 35.68 31.53 25.88 24.96 23.21 22.93 16.66
Return on Assets (%) 5.29 12.81 17.81 18.00 14.28 15.13 14.98 14.27 10.28

Balance Sheet View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Shh. Funds 163 167 212 278 464 559 679 840 971 1,089
Non Curr. Liab. 130 94 64 56 32 47 35 44 49 59
Curr. Liab. 100 133 131 111 65 99 65 60 68 60
Minority Int. 3 4 4 5 21 23 26 28 62 52
Equity & Liab. 396 398 412 450 583 727 805 971 1,149 1,260
Non Curr. Assets 302 306 307 311 440 517 523 596 633 656
Curr. Assets 94 92 104 140 143 211 282 376 516 604
Misc. Exp. not W/O
Total Assets 396 398 412 450 583 727 805 971 1,149 1,260

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-06 Rs. Cr. TTM
Net Sales 239 223 294 329 391 420 444 502 529 513
Other Income 2 3 1 3 3 6 6 9 6 7
Total Income 241 226 295 332 394 425 450 511 536 521
Total Expenditure -138 -133 -156 -178 -227 -237 -241 -269 -327 -344
PBIDT 103 93 139 154 166 188 209 241 209 177
Interest -13 -9 -8 -4 -9 -5 -4 -3 -3 -2
Depreciation -10 -9 -9 -13 -18 -21 -26 -29 -35 -35
Taxation -7 -23 -41 -44 -45 -46 -46 -59 -47 -38
Exceptional Items -51 -4
PAT 21 52 77 93 94 116 133 151 124 102
Minority Interest -1 -1 -1 -1 -3 -5 -4 -5 -4 -2
Share Associate
Other Related Items
Consolidated Net Profit 20 51 76 92 90 111 129 146 120 99
Adjusted EPS 2 5 7 8 8 10 12 13 11 9

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 41 56 54 93 107 116 129 141 163 122
Cash Fr. Inv. -30 -9 -11 -5 -60 -78 -125 -45 -26 -25
Cash Fr. Finan. -5 -33 -36 -63 -65 -2 -43 -39 -26 -27
Net Change 7 13 6 26 -18 36 -39 58 111 70
Cash & Cash Eqvt 3 2 4 25 8 61 23 83 192 267

Shareholding Pattern View Details >>

9 Qtrs 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%)
Promoter 58.13 55.45 55.39 55.38 52.30 52.55 52.71 52.70 52.70
Public 41.87 44.55 44.61 44.62 47.70 47.45 47.29 47.30 47.30
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Tue, 09 Aug 2022
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Furtherance to our intimation letter dated August 02 2022 please find enclosed the Transcript of the Conference call held on Saturday August 06 2022 with Analysts and Investors for the un-audited Financial Results of the Company for the quarter ended June 30 2022.
Mon, 08 Aug 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed copy of the newspaper publication of Extract of Un-audited Consolidated Financial Results for the quarter ended June 30 2022 published in The Free Press Journal and Navshakti on August 07 2022.
Sat, 06 Aug 2022
Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results Of The Company (Standalone And Consolidated) For The Quarter Ended June 30 2022
With reference to the Board meeting notice dated July 30 2022 we hereby inform that the Board of Directors in its meeting held on August 06 2022 (commenced at 10:00 a.m. and concluded at 10:45 a.m.) has inter-alia approved the Unaudited Financial Results of the Company (Standalone & Consolidated) for the quarter ended June 30 2022.

In view of the aforesaid we hereby enclose the following:
Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30 2022 along with the Limited Review Report issued by M S K A & Associates Statutory Auditors of the Company.

This is for your information and for public at large.

Technical Scans View Details >>

Fri, 12 Aug 2022
High Delivery Percentage High Delivery Percentage
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Year High Decrease 1 Year
CCI Oversold Zone CCI Oversold Zone

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,167.25 914.60 +0.1%
Divi's Laboratories Ltd. 98,918.90 3,732.00 +0.2%
Cipla Ltd. 82,906.37 1,031.05 +0.4%
Dr. Reddy's Laboratories Ltd. 70,920.35 4,297.80 +0.9%
Apollo Hospitals Enterprise Ltd. 62,010.73 4,349.40 +0.8%
Torrent Pharmaceuticals Ltd. 51,917.53 1,569.90 +2.0%
Piramal Enterprises Ltd. 45,855.65 1,926.70 +0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 56.35 914.60 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 33.43 3,732.00 +0.2%
Cipla Ltd. Consolidated 2022-06 33.32 1,031.05 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 23.69 4,297.80 +0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 70.15 4,349.40 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 64.82 1,569.90 +2.0%
Piramal Enterprises Ltd. Consolidated 2022-06 24.38 1,926.70 +0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 4.37 914.60 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8.44 3,732.00 +0.2%
Cipla Ltd. Consolidated 2022-06 3.86 1,031.05 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 3.50 4,297.80 +0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 10.43 4,349.40 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 8.12 1,569.90 +2.0%
Piramal Enterprises Ltd. Consolidated 2022-06 1.28 1,926.70 +0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.02 914.60 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,732.00 +0.2%
Cipla Ltd. Consolidated 2022-03 0.04 1,031.05 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,297.80 +0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,349.40 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,569.90 +2.0%
Piramal Enterprises Ltd. Consolidated 2022-03 1.56 1,926.70 +0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 914.60 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,732.00 +0.2%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.05 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,297.80 +0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,349.40 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,569.90 +2.0%
Piramal Enterprises Ltd. Consolidated 2022-03 3.87 1,926.70 +0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 914.60 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,732.00 +0.2%
Cipla Ltd. Consolidated 2022-03 13.10 1,031.05 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,297.80 +0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,349.40 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,569.90 +2.0%
Piramal Enterprises Ltd. Consolidated 2022-03 3.87 1,926.70 +0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 914.60 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,732.00 +0.2%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,031.05 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,297.80 +0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,349.40 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,569.90 +2.0%
Piramal Enterprises Ltd. Consolidated 2022-03 13,993.30 1,926.70 +0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 914.60 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,732.00 +0.2%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,031.05 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,297.80 +0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,349.40 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,569.90 +2.0%
Piramal Enterprises Ltd. Consolidated 2022-03 1,345.89 1,926.70 +0.3%

FAQ's On Advanced Enzyme Technologies Ltd.

Can I Buy Advanced Enzyme Shares now?

What is the Share Price of Advanced Enzyme?

What is the Relative Strength Index (RSI) Value of Advanced Enzyme?

What is the Market Capital (MCAP) of Advanced Enzyme?

What are the key metrics to analyse Advanced Enzyme?

What is the Price Performance of Advanced Enzyme?